Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.60 |
| ▸ | NT5E | P21589 | 8/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10693613 | 0.80 | KDM4E (0.69) | ADORA3ADORA2AADORA2B | |
| SCHEMBL6300238 | 0.80 | KDM4E (0.69) | ADORA3ADORA2AADORA2B | |
| SCHEMBL29086896 | 0.79 | LMNA (0.53) | NT5EADORA3ADORA2AADORA2B | |
| SCHEMBL1140717 | 0.76 | SLC29A1 (0.64) | PDE2AADORA3ADORA2ASLC29A1 | |
| SCHEMBL622588 | 0.75 | ADORA1 (0.69) | PDE2AADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL6293320 | 0.74 | HTR1A (0.56) | PDE2A | |
| SCHEMBL1533274 | 0.74 | HINT1 (0.73) | PDE2ANT5EADORA2AADORA2B | |
| SCHEMBL21192264 | 0.73 | SLC29A1 (0.62) | PDE2AADORA3SLC29A1 | |
| SCHEMBL8902195 | 0.73 | ADORA3 (0.62) | NT5EADORA3ADORA2ASLC29A1 | |
| SCHEMBL19488390 | 0.73 | SLC29A1 (0.62) | PDE2AADORA3SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306525-A2 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-10981944-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3399984-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
| WO-2017120508-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | PDE2A 142/4885NT5E 3/4885ADORA3 37/4885 |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | PDE2A 137/4885NT5E 3/4885ADORA3 35/4885 |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | PDE2A 137/4885NT5E 3/4885ADORA3 35/4885 |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | PDE2A 137/4885NT5E 3/4885ADORA3 35/4885 |
| US-10981944-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | PDE2A 142/4885NT5E 3/4885ADORA3 37/4885 |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | PDE2A 137/4885NT5E 3/4885ADORA3 35/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | PDE2A 142/4885NT5E 3/4885ADORA3 37/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | PDE2A 142/4885NT5E 3/4885ADORA3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.